METABOLIC
Semaglutide
Explore compounded semaglutide injections for weight management, with clinical review, medication, shipping and ongoing care in one monthly plan.
From $129/mo
Injection
Compounded tirzepatide injections
Explore compounded tirzepatide injections for weight management, with clinical review, medication, shipping and ongoing care in one monthly plan.
Your treatment plan
From $169/month equivalent
$507 billed every 3 months3-month commitment$199 billed monthly also availableAll fees includedView plan details
- Licensed clinicians
- Compounded by a licensed 503A pharmacy
- No clinic visit
Compounded semaglutide and tirzepatide are not FDA-approved products. They are prescribed by licensed clinicians based on individual clinical evaluation and prepared by a licensed 503A pharmacy. Not all patients qualify.
Questions before you start?
Compare this treatmentWhat will I pay?
Standard plan price$169 per month equivalent, billed $507 every 3 months. 3-month commitment.
Billing options and renewal
The standard Tirzepatide price is $199 billed monthly, or $507 paid up front every three months ($169 per month equivalent; a three-month commitment). These are recurring prices before any eligible first-order discount. A first-order offer reduces that order only; renewal uses the standard price for the chosen plan. A monthly equivalent is not a monthly charge.
What should I know about this treatment?
Explore compounded tirzepatide injections for weight management, with clinical review, medication, shipping and ongoing care in one monthly plan.
Read the evidence and its limitationsWhat should I review before starting?
Boxed warning
FDA-approved tirzepatide products carry a boxed warning about thyroid C-cell tumors observed in rats; whether tirzepatide causes these tumors in humans is unknown. That warning is why a personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication, and why pancreatitis history, pregnancy plans, significant gastrointestinal disease, and any glucose-lowering medication are reviewed before prescribing.
A licensed clinician reviews your health history and medications and determines whether treatment is appropriate for you.
Read the full Important Safety InformationHow do I request Tirzepatide online?
Complete the online assessment with your health history, current medications and treatment goals. A licensed clinician reviews the information and decides whether to prescribe. If prescribed, a licensed pharmacy prepares and ships your medication.
See how care worksWhat It Is
Less guesswork. A plan built around you.
When hunger keeps pulling you away from your goals, it is worth discussing the medical options. Tirzepatide acts on both GIP and GLP-1 receptors involved in appetite and glucose regulation.
AnthologyRX offers compounded tirzepatide injections. Your independent licensed clinician reviews your health history, medications, goals and any previous GLP-1 treatment, then evaluates whether a compounded preparation meets an individual medical need.
Your plan includes clinical review, prescribed medication, pharmacy fulfillment, shipping and care-team messaging. Your clinician directs dosing and adjustments, while you keep building the nutrition, movement and strength habits that support your goals.
This is a compounded prescription, not an FDA-approved finished drug product. Studies of approved medicines help explain the treatment landscape but do not establish equivalent results for this preparation.
Read the evidenceWho It's For
For when appetite is biology, not a character test.
01
The Biology-First Patient
Your nutrition plan is not a mystery and your effort is not the missing ingredient. You want a clinician to evaluate the appetite and glucose signaling underneath the struggle.
02
The Prior GLP-1 Patient
You have experience with a single-pathway incretin medication and want the next decision made from that history. Tirzepatide gives your provider a different receptor profile to consider.
03
The Long-Game Planner
You are not looking for a dramatic month. You want a medical plan that can be reviewed, adjusted, and eventually reconsidered as your goals and health change.
Compounded tirzepatide is not an FDA-approved drug product. Candidacy, dose, and how it sequences with anything else you take are determined by a licensed provider from your full assessment.
This might not be the right fit if:
- Personal or family history of medullary thyroid carcinoma or MEN 2
- History of pancreatitis
- Pregnancy, planned pregnancy, or breastfeeding
- Severe gastrointestinal disease, including gastroparesis
- Type 1 diabetes or insulin-dependent regimens without specialist oversight
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
Your Plan
Tirzepatide, prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- Format
- Injection
- Billed amount
- $507 every 3 months
- Monthly equivalent
- $169 per month
- Commitment
- 3 months
- Monthly option
- $199 billed monthly · 1 vial total plan quantity
- Fees
- Included in the plan price
Compounded by a licensed 503A pharmacy
Tirzepatide
Injection · Titration program / Ongoing Treatment program
From $169
Monthly equivalent. All fees included.
$507 billed every 3 months. 3-month commitment.
- Licensed clinician review of your history, medications, goals, and prior incretin use
- Individual decision on whether compounded tirzepatide is appropriate
- Preparation by a licensed 503A pharmacy if prescribed
- Clinician-directed treatment changes based on response and tolerability
- Ongoing review of the broader metabolic plan
$169 /mo equivalent · 3-month commitment
$169/mo equivalent, all-in. Consultation is included in the plan price, not added on top. Consultation, cancellation and refund policy.
What happens when I start?
You'll begin an online assessment for Tirzepatide.
- Tell your clinician about you. Share your goals, health history and current medications.
- Review your plan. Confirm the treatment option, billing interval and total shown in the assessment.
- Get an individual clinical review. Your clinician decides whether to prescribe. If prescribed, a licensed pharmacy fulfills your prescription.
Starting an assessment doesn't guarantee a prescription. How care works
Compounded semaglutide and tirzepatide are not FDA-approved products. They are prescribed by licensed clinicians based on individual clinical evaluation and prepared by a licensed 503A pharmacy. Not all patients qualify.
*Price reflects a 3-month commitment. See billing details above.
Your subscription renews at your selected billing interval. Cancel through your member dashboard before the next billing date to stop future charges. Cancellation does not refund the current billing period. See cancellation and refund terms.
Have a question about this plan?
Clinical questions
Message your provider about dosing, side effects, your response or changes in your health.
Open patient portalNew to AnthologyRX? Ask our team about getting started.
Care and cost
Clear pricing. Care that follows through.
Your plan brings the clinical review, prescribed medication, pharmacy fulfillment, shipping and care-team messaging together. The consultation is included in your plan price.
- What will I pay at the start and on renewal?
- $199 billed monthly, or $507 paid up front every three months ($169/month equivalent; three-month commitment). These are the standard recurring prices, before any eligible first-order discount. The monthly equivalent is not a monthly charge.
- Does a dose change affect the price?
- The standard injection price stays the same across the dose stages we currently offer. Your clinician adjusts treatment according to your response and side effects; a higher dose is not a required next step. Moving to a different product or formulation can change the price.
- How is this formulation different?
- Current injectable options combine tirzepatide with vitamin B12 or glycine. Your clinician selects the preparation for your needs. Follow the ingredients, concentration and directions on your prescription label. Explore our other tirzepatide preparations: Dissolving tablets or Lower-dose injections with B12. Each requires its own clinical evaluation.
- Who helps when I have a question?
- Use the patient portal for questions about dosing, side effects or changes in your health. AnthologyRX support can help with billing, shipping and portal access.
The people behind your care
Guidance from the first question onward.
Independent clinical care
Licensed clinicians affiliated with Arora Health & Aesthetics, LLC review your health history, medications and goals, then discuss whether Tirzepatide or another approach fits your needs.
Medical information on this page reviewed by Dr. Dylan Russell, MD, Chief Health Officer on . Your prescribing clinician provides your individual care.
Verify Dr. Russell's medical licensePharmacy quality that matters
Prepared to your prescription by a licensed compounding pharmacy. Our partners have verified quality programs covering identity, potency, independent testing and batch documentation, with sterility and endotoxin controls for injectable preparations.
Compounded preparations are not FDA-approved. Pharmacy quality controls and your clinician's evaluation of treatment evidence each have a role in your care.
Pharmacy & fulfillment
Listed dispensing pharmacy
- BelieveRXFormulation: Tirzepatide, injectionVerify: Texas pharmacy license 35264
Availability depends on your prescription and location. For pharmacy questions, contact our team.
A direct line for follow-up
Message your provider through the patient portal about dosing, side effects, your response or changes in your health. Contact AnthologyRX support for billing, shipment or portal-access help.
The Evidence
What the research shows
Tirzepatide is one peptide that activates both the GIP and GLP-1 receptors.
Both native incretin receptors
the GIP and GLP-1 receptors, the targets of the two native incretin hormones
The detail
Tirzepatide is a single peptide that binds to and activates both the GIP receptor and the GLP-1 receptor, the targets of the two native incretin hormones.1
GIP and GLP-1 are gut peptides that produce the incretin effect after nutrient intake.
The detail
GIP and GLP-1 are gut peptides secreted after nutrient intake, GIP from K cells of the upper intestine and GLP-1 from L cells of the lower intestine, and together they produce the incretin effect, the larger insulin secretory response to oral than to intravenous glucose; GLP-1 is also glucagonostatic.2
Labeling says tirzepatide raises insulin, lowers glucagon and delays gastric emptying.
The detail
Approved tirzepatide labeling states that the molecule enhances first- and second-phase insulin secretion and reduces glucagon, both in a glucose-dependent manner, and that it delays gastric emptying, an effect largest after the first dose that diminishes over time.1
Labeling calls GLP-1 an appetite regulator; the GIP contribution rests on animal studies.
The detail
The same class of labeling describes GLP-1 as a physiological regulator of appetite and caloric intake, notes that GIP and GLP-1 receptors are found in areas of the brain involved in appetite regulation, and attributes the further contribution of GIP to food-intake regulation to nonclinical studies, with distribution to appetite-related brain regions shown in animal studies.3
A five-day half-life is what enables once-weekly dosing, not any outcome.
Five days
elimination half-life described as enabling once-weekly dosing
The detail
For pharmacokinetics, labeling attributes the dosing interval to molecular design rather than to any outcome: a C20 fatty diacid enables albumin binding, the molecule is described as highly bound to plasma albumin, and the elimination half-life of approximately five days is described as enabling once-weekly dosing, with steady state reached after four weeks of once-weekly administration.1
What it does not show
A compounded preparation is not an FDA-approved drug product.
The detail
A compounded preparation is not an FDA-approved drug product, and FDA does not verify the safety, effectiveness or quality of a compounded drug before it is marketed.4
Everything above describes how the molecule works, not what any trial measured.
The detail
Every statement above is drawn from the clinical pharmacology section of approved labeling, a section separate from the clinical studies section of the same document. This block deliberately describes how the molecule works and does not report what any trial measured.1
Dual agonism is a statement about receptor binding, not a claim of superior results.
The detail
Dual agonism means one molecule occupies two incretin receptors, a property characterized in vitro through receptor-occupancy analysis and cell signalling assays. It is a statement about receptor binding rather than a claim of results superior to agonism at the GLP-1 receptor alone.5
The GIP role in food intake was established in mice, not in humans.
The detail
The central nervous system role of GIP receptor signalling in the control of food intake was established in mice, and rodent findings of that kind do not establish human outcomes.6
None of the sources above evaluated a compounded preparation.
The detail
Approved-product labeling describes the pharmacokinetics and quality attributes of that finished product. It does not describe the exposure, potency or content of a preparation compounded to an individual prescription, and none of the sources above evaluated such a preparation.4
- FDA-approved tirzepatide injection prescribing information, sections…DailyMed
- Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018.
- FDA-approved tirzepatide injection prescribing information, section…DailyMed
- FDA, Compounding and the FDA: Questions and Answers.FDA
- Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor… JCI Insight. 2020. In vitro receptor pharmacology.
- Zhang Q, Delessa CT, Augustin R, et al. The glucose-dependent insulinotropic polypeptide (GIP) regulates body… Cell Metab. 2021.e5. Mouse study.
Important Safety Information
Boxed warning
FDA-approved tirzepatide products carry a boxed warning about thyroid C-cell tumors observed in rats; whether tirzepatide causes these tumors in humans is unknown. That warning is why a personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication, and why pancreatitis history, pregnancy plans, significant gastrointestinal disease, and any glucose-lowering medication are reviewed before prescribing.
Do not use if you have
- A personal or family history of medullary thyroid carcinoma or MEN 2
Serious risks
- Pancreatitis
- Gallbladder disease
- Severe gastrointestinal reactions
- Kidney injury related to dehydration
- Hypoglycemia when tirzepatide is used with insulin or insulin secretagogues
Commonly reported
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
Because it is a compounded preparation
- This preparation is compounded rather than an FDA-approved finished drug product, so it has no safety database of its own
The effects patients report most often are gastrointestinal, most often during titration. The important risks in tirzepatide labeling are listed here. The prescribing judgment stays with your clinician.
Questions
Asked and answered.
Explore
More in Metabolic.
METABOLIC
Semaglutide + B12 Microdose
A lower-dose compounded semaglutide and vitamin B12 injection, with individual prescribing, pharmacy fulfillment and follow-up.
From $109/mo
METABOLIC
Tirzepatide + B12 Microdose
A lower-dose compounded tirzepatide and vitamin B12 injection, with individual prescribing, pharmacy fulfillment and follow-up.
From $149/mo
